|
Biological Ontologies
|
D064229 |
[Structured vocabularies describing concepts from the fields of biology and relationships between concepts.
] |
|
Endothelin-1
|
D12.644.276.400.225 |
|
|
Microscopic Polyangiitis
|
C14.907.253.329.600 |
|
|
Antibody-Producing Cells
|
A15.382.032 |
|
|
Arachidonic Acid
|
D10.251.355.310.166.100 |
|
|
Social Marketing
|
D040241 |
[Use of marketing principles also used to sell products to consumers to promote ideas, attitudes and behaviors. Design and use of programs seeking to increase the acceptance of a social idea or practice by target groups, not for the benefit of the marketer, but to benefit the target audience and the general society.
] |
|
Galvanic Skin Response
|
E05.796.332 |
|
|
Secondary Metabolism
|
D064210 |
[A physiochemical process which occurs in a wide range of organisms which unlike BASAL METABOLISM is not required for or essential to short-term survivability but to long-term general well-being of the organism.
] |
|
Connectin
|
D064211 |
[A giant elastic protein of molecular mass ranging from 2,993 kDa (cardiac), 3,300 kDa (psoas), to 3,700 kDa (soleus) having a kinase domain. The amino- terminal is involved in a Z line binding, and the carboxy-terminal region is bound to the myosin filament with an overlap between the counter-connectin filaments at the M line.
] |
|
Native Polyacrylamide Gel Electrophoresis
|
E05.301.300.319.725 |
|
|
Eye Injuries
|
C10.900.300.284.250 |
|
|
Risk Reduction Behavior
|
D040242 |
[Reduction of high-risk choices and adoption of low-risk quantity and frequency alternatives.
] |
|
Potentially Inappropriate Medication List
|
N04.761.700.615 |
|
|
Salmonella paratyphi A
|
B03.440.450.425.800.200.600 |
|
|
Reticulocyte Count
|
G09.188.105.330.725 |
|
|
Erythrocyte Count
|
G09.188.105.330 |
|
|
Central Nervous System Sensitization
|
G11.561.148 |
|
|
Voltage-Gated Sodium Channel Blockers
|
D27.505.954.411.720.500 |
|
|
Sodium Channel Blockers
|
D27.505.954.411.720 |
|
|
Licensure, Pharmacy
|
N03.706.110.510.560 |
|
